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Abstract
Background: Outbreaks of hepatitis E frequently occur in tropical developing countries during the rainy season
due to overflowing drains, short-circuiting of networks of clean water and use of contaminated water from wells.
Hepatitis E virus (HEV) infections are usually accompanied by general symptoms of acute liver disease. This study
was conducted to define the clinical and epidemiological aspects of the HEV outbreak that occurred in May 2004
in Bangui.
Methods: Blood samples were collected from 411 patients aged 1-87 years, most of whom presented with
jaundice, asthenia or signs of uncomplicated malaria, for a transversal study from June 2004 to September 2005.
Patients were recruited at 11 health care centres, including two referral hospitals, after they had given informed
consent. The diagnosis of HEV was made with a commercial ELISA test to detect IgM and/or IgG antibodies. HEV
RNA was amplified by RT-PCR to confirm the presence of the viral genome.
Results: The most frequent clinical signs found were jaundice (93.4%), vomiting (50.7%), hepatalgia (47.4%),
hepatomegaly (30.9%) and asthenia (26.8%), which are the general clinical signs of hepatic disease. Acute hepatitis
E was found in 213 patients (51.8%) who were positive for HEV IgM antibodies. The IgG anti-HEV seroprevalence
during this outbreak was high (79.5%). The age group 18-34 years was more frequently infected (91.2%) than those
aged 1-17 (78.0%) or over 34 (64.9%) (p < 10
-6). RT-PCR performed on 127 sera from the 213 IgM-HEV-positive
patients was amplified, and the presence of the viral genome was found in 65 samples.
Conclusion: Although no specific clinical signs exist for hepatitis E infection, people presenting with jaundice,
vomiting, hepatalgia, asthenia, hepatomegaly or distended abdomen with no signs of uncomplicated malaria in
tropical developing countries should be sent to a laboratory for testing for hepatitis E.
Background
Hepatitis E virus (HEV), a small, single-stranded, hepa-
totropic RNA virus, currently classified in the genus
Hepevirus [1], is responsible for enteric non-A non-B
hepatitis in humans. Infection with HEV, thought to
spread via the faecal-oral route, causes outbreaks that
have been linked to waterborne sources in developing
countries; sporadic cases have also been seen [2].
Although the potential for zoonotic and cross-species
transmission has been demonstrated [3,4], asymptomatic
carriers of HEV have been reported, and such cases are
potential human reservoirs of the virus [5]. During epi-
demics, the person-to-person transmission rate appears
to be low, although intrafamilial transmission is possible
[6]. The course of the disease is generally self-limiting;
however, chronic HEV infection has been reported in
immunocompromised patients [7-10]. Reports have indi-
cated an increased risk for disease and as high as 10-
20% case mortality from fulminant hepatitis during the
third trimester of pregnancy [11].
Outbreaks of hepatitis E frequently occur in tropical
Africa during the rainy season due to overflowing
drains, short-circuiting of networks of clean water and
use of contaminated water from wells [12-14]. The Cen-
tral African Republic (CAR), located in tropical Africa,
is considered to be an area of high endemicity for the
main infectious diseases, including infections with HIV
[15], hepatitis B virus and other hepatotropic viruses
[16,17], yellow fever [18], malaria [19], tuberculosis [20]
and other infections [21-23]. No HEV epidemics were
documented in the CAR before 2001, although HEV
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adults [24]. The first outbreak of this disease in the
CAR was reported in 2001 [25,26], and a further out-
break occurred in 2004.
In order to improve the diagnosis of hepatitis E in
CAR, the aim of this study was to determine the clinical
and epidemiological characteristics of HEV infection
during the outbreak in Bangui.
Methods
Study population
One month after the beginning of the 2004 outbreak, 411
patients residing in or around Bangui, aged 1-87 years
(average age, 27.9 ± 5.1), were clinically examined by phy-
sicians in 11 health care centres, including two national
referral hospitals, and completed a questionnaire to pro-
vide sociodemographic information, including gender, age
and place of residence (district in Bangui). During stan-
dard clinical screening, all persons enrolled in the study
were also questioned about their history of symptomatic
hepatitis. The main criteria for inclusion in the study were
gastrointestinal complaints and fever, leading to a clinical
diagnosis of malaria with ineffective malaria treatment.
Other inclusion criteria were jaundice, anorexia, diarrhoea,
nausea or severe asthenia. Individuals should also have
had no history of exposure to blood, such as transfusion.
Informed consent was obtained from all patients
included in the study. For those under 18, parental con-
sent was obtained. Each participant or parent was
informed of the results of the serology. The study was
approved by the Medical Committee of the Institut Pas-
teur in Paris (France) because of, until the third trimester
of 2006, the Central African Republic did not have his
own Ethics Committee. Before that time, all the research
projects at the Institut Pasteur de Bangui (which is
related to Institut Pasteur in Paris, France) were sub-
mitted to the Ethics Committee of the Institut Pasteur in
Paris (France). Once ethical approval was received,
administrative authorization was obtained from the Min-
istry of the Public Health of the Central African Republic.
Clinical observations
Patients were examined for jaundice, hepatalgia, vomiting,
asthenia, fever, arthralgia, abdominal pain, nausea, anor-
exia, diarrhoea or headache. They were then examined
physically for hepatomegaly, distended abdomen, spleno-
megaly, oedema of lower limbs, encephalopathy or dete-
rioration of general condition. Physicians could also report
any clinical observation not listed in the questionnaire.
Specimen collection
Blood and stool samples were collected from patients
who fulfilled the inclusion criteria over 16 months
between June 2004 and September 2005.
Biological testing
A diagnosis of acute hepatitis E was based on serology.
IgM and IgG HEV were detected with a commercial
ELISA assay (Bioelisa, Biokit, Spain). Amplification of
HEV RNA by RT-PCR was performed to confirm a
recent HEV infection. Serum samples were also analysed
for AST and ALT. Malaria, hepatitis B and C, and yel-
low fever were ruled out.
Statistical analysis
Epi-Info Version 2000 (CDC, USA & WHO, Geneva,
Switzerland) software was used to analyse data on pre-
valence, with 95% confidence intervals, and the chi-
square test was used for the comparison of variables
and associations with HEV positivity. Statistical signifi-
cance was assumed at p < 0.05.
Results
The sex ratio was of 1 (1:1) with 50.9% males (209) and
49.1% females (202). Serology results showed that more
males were infected during the outbreak than females.
IgM anti-HEV antibodies, which predominate in the pri-
mary immune response and define acute infection, were
detected in the sera of 118 men (56.4%) and 95 women
(47.0%). The observed difference was not significant.
However, males had a higher IgG anti-HEV seropreva-
lence (85.1%) than females (73.8%), and the risk for
infection was clearly higher in males than females (OR
2.04; 95% CI 1.21-3.45; p < 0.005) during the period of
study.
Table 1 shows the distribution of HEV serology (IgM
and IgG) according to age. The age group 18-34 years
were more frequently IgM-HEV positive than the other
age groups (1-17 and > 34 years) (p < 0.001).
Amplification by RT-PCR of 127 serum and 25 stool
samples positive for IgM-HEV antibody showed that 50
sera and 24 stool samples were positive, indicating that
the viral genome was present.
More than 80% of patients with positive IgM anti-
HEV antibody had higher ALT (82.1%) and AST (86.8%)
values than normal.
The clinical features observed in patients positive for
IgM-HEV are listed in Table 2. Although no specific
symptoms were reported during the outbreak, jaundice
Table 1 Distribution of 411 patients according to
serology during the outbreak of hepatitis E in Bangui in
2004
Age (years) IgM positive (%) IgG positive (%) Total
1-17 28 (56.0) 39 (78.0) 50 (12.2%)
18-34 126 (61.7) 186 (91.2) 204 (49.6%)
> 34 59 (37.6) 102 (64.9) 157 (38.2%)
Total 213 (51.8%) 327 (79.5%) 411
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vomiting (50.7%), hepatalgia (47.4%), asthenia (26.8%)
and physical signs like hepatomegaly (30.9%) and dis-
tended abdomen (14.5%).
To determine how long the infection persisted in the
population, variations in IgM HEV positivity were
monitored for 16 months, from June 2004, 1 month
after the beginning of the outbreak, to September 2005
(Figure 1). The number of cases with IgM-HEV peaked
in July 2004, September 2004 and March 2005.
Between October 2004 and February 2005, between
the two outbreaks, the level of infection remained con-
stant at the background level.
In order to define the HEV-infected area, we collected
blood and stools in different health care centres in the
eight districts of Bangui, each of which has at least one
public health care centre. As shown in Figure 2, IgM-
HEV was detected in patients from almost all districts
of Bangui; however, more patients in the fourth and
seventh districts presented for medical examination, and
higher percentages of HEV infection were found in the
seventh and eighth districts.
Discussion
During the 2004 outbreak of hepatitis E, more than 51%
of patients were infected with HEV. The most frequent
clinical and biological signs were jaundice, vomiting,
hepatalgia, hepatomegaly, asthenia, distended abdomen,
fever and high levels of transaminases. A possible limita-
tion of this study is the wide inclusion criteria, as physi-
cians at the health care centres could include all patients
who presented with jaundice or uncomplicated malaria.
It is possible that this inclusion criterion biased our
Table 2 Clinical features in 411 patients clinically
examined during the outbreak of hepatitis E in Bangui in
2004
Clinical characteristics Positive IgM-HEV (n = 213)
Clinical signs
Jaundice (n = 353) 199 (93.4%)
Vomiting (n = 213) 108 (50.7%)
Hepatalgia (n = 212) 101 (47.4%)
Hepatomegaly (n = 142) 66 (30.9%)
Fever (n = 56) 31 (14.5%)
Abdominal pain (n = 18) 9 (4.2%)
Dark urine (n = 16) 8 (3.7%)
Nausea (n = 11) 7 (3.3%)
Itching (n = 9) 6 (2.8%)
Encephalopathy (n = 10) 5 (2.3%)
Myalgia (n = 3) 3 (1.4%)
Hemorrhage (n = 6) 1 (0.5%)
Discolored stools (n = 4) 1 (0.5%)
Clinical symptoms
Asthenia (n = 84) 57 (26.8%)
Distended abdomen (n = 64) 31 (14.5%)
Epigastralgia (n = 19) 12 (5.6%)
Arthralgia (n = 19) 11 (5.2%)
Anorexia (n = 10) 8 (3.7%)
Limb oedema (n = 25) 7 (3.3%)
Headache (n = 10) 4 (1.9%)
Diarrhoea (n = 7) 4 (1.9%)
Ascites (n = 5) 3 (1.4%)
Splenomegaly (n = 5) 1 (0.5%)
Deterioration of general condition (n = 5) 0
Cutaneous eruption (n = 1) 0
Percentages of total of positive IgM (213)

Figure 1 Evolution of IgM-HEV serology during 16 months,
between June 2004 and the beginning of the outbreak to
September 2005. Blue represents the total numbers of patients;
red shows the number with detected IgM-HEV.
Figure 2 Locations of patients with positive IgM-HEV in Bangui
and suburbs. Black represents the total number of patients; purple
shows the number of patients who were IgM-HEV antibody-positive.
Patients were from all eight districts of Bangui. *Other districts: first,
second and third districts **ND district: district not determined.
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included or did not enter the defined categories. Never-
theless, the rate of IgM-HEV obtained was very high and
was in accordance with that previously reported; e.g. 42%
of patients were infected at the time of an epidemic of
hepatitis E in Namibia [14].
The high prevalence of jaundice among our patients
may be explained by the fact that CAR patients are more
aware of this sign, because it is usually related to yellow
fever and thus requires urgent medical examination. A
study conducted in Pakistan [27] also showed that jaun-
dice was present in almost all patients with HEV IgM
positive serology. This sign was also found in 10 IgM-
HEV-positive patients in Nigeria [28]. Our study shows,
however, that the presence of jaundice cannot confirm
HEV infection, and vomiting, hepatalgia, asthenia, fever,
elevated ALT levels and hepatomegaly, distended abdo-
men and fever must also be present [29]. As previously
reported [30], we also found that adolescents and young
adults were preferentially infected by HEV during the epi-
demic. This observation suggests that active people are
more readily in contact with the virus, especially in tropi-
cal developing countries. In these countries, many people
are farmers, who may be a source of contamination by
HEV, because poultry and swine farmers, other profes-
sionals with an occupational activity related to farming
and veterinarians are occupational risk groups and are
more heavily exposed to HEV than other professions
[31-35].
Biochemical determination of hepatic cytolysis by the
detection of high levels of transaminases is an impor-
tant parameter in the control of liver disease. In our
study, the level of transaminases was four to five times
higher than normal in more than three quarters of the
infected patients. This confirms the presence of hepatic
cytolysis, which usually accompanies infection with
hepatitis viruses [36]. RT-PCR was not positive in all
cases with IgM HEV, confirming that detection of the
viral genome is generally difficult after the beginning
of symptoms during epidemics of hepatitis E [37]. Our
results could not formally link HEV infection to trans-
aminases, because of the prevalence of many other
infectious diseases, including other types of hepatitis,
yellow fever and malaria, which may also increase
hepatic enzymes [38].
The main inclusions occurred in July and September
2004 and March 2005, which correspond to the peaks of
infection and were linked to positive IgM-HEV serology.
In Bangui, the rainy season starts in May and finishes in
December, and a recrudescence of cases of acute hepati-
tis E is observed during that period in tropical countries,
due to overflowing drains and short-circuiting of net-
works of clean water and structures for purifying waste-
water. The level of endemicity results in high IgG anti-
HEV seroprevalences. As there is generally a single
source of contamination, generally from water, epi-
demics of hepatitis E are characterized by spectacular
numbers of infected people [37,39,40]. The lack of sam-
ples during August was probably related to the absence
of health professionals, who take their annual vacation
at this time. The outbreak may therefore have peaked
during August, and the peak observed in September
might be only the downward part of the curve of infec-
tion. The period between October 2004 and February
2005 represents the inter-epidemic season. Asympto-
matic excretion of HEV particles in the stools and the
environmental reservoir of the HEV may explain the
background noise observed and circulation of the virus.
Most patients came from the fourth and seventh dis-
tricts of Bangui, but more cases of HEV infection were
detected in patients living in the seventh and eighth dis-
tricts. As the disease is related to exposure to faeces,
hepatitis E is endemo-epidemic in areas where collective
hygiene is badly monitored [3]. During epidemics, inges-
tion of viral particles by consumption of contaminated
water is the principal mode of transmission, and more
rarely by food soiled by human excreta. The seventh
and eighth districts often have problems of overflowing
drains and short-circuiting of networks of clean water
and of structures to purify wastewater. Latrines are built
close to wells, and water is usually used without treat-
ment. All these insalubrities might explain the presence
of the virus and the high rate of infection of the popula-
tion in these two districts. Further, larger studies are
necessary to determine the distribution of HEV in the
districts of Bangui and to investigate the sources of the
frequent outbreaks of HEV in this city since the first
outbreak described in the suburbs in 2001 [25,26].
Conclusion
This study shows that there are no specific clinical or phy-
sical symptoms that might allow clinicians to diagnose
hepatitis E. The clinical signs, dominated by jaundice,
vomiting, hepatalgia and asthenia, are not specific to HEV
infection, but could orient the clinician in the event of an
association with an evocative epidemiological context. In
order to avoid repetitive outbreaks and epidemics of hepa-
titis E in Bangui, it would be desirable to reinforce the pre-
ventive measures of individual and collective hygiene and
to set up a monitoring system for this pathology.
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